DE-INCYTE
Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from clinical trials of medicines that are being developed in-house and through partnerships with Novartis, MorphoSys and Takeda will be presented at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31); and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14).
“We are pleased to have virtual platforms such as ASCO20 and EHA25 to continue sharing important data with the scientific community in a timely manner,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “These data demonstrate the strength of our broad oncology portfolio and our partnerships; and reinforce our commitment to finding solutions that can help meet patients’ needs.”
Key abstracts accepted by ASCO and EHA include:
ASCO Abstracts
Oral, poster discussion and poster sessions, as well as track-based clinical science symposia, accepted for presentation at ASCO will be available on demand beginning Friday, May 29, 2020, 8:00 AM ET.
Oral Presentations
Capmatinib in Patients with High-Level MET -Amplified Advanced Non-Small Cell Lung Cancer (NSCLC): Results from the Phase 2 GEOMETRY mono-1 Study (Abstract #9509, Session: MET Mutations: The Meat of the Matter)1
Interim Analysis (IA) of OPTIC: A Dose-Ranging Study of Three Ponatinib (PON) Starting Doses (Abstract #7502, Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant)2
E-Poster Presentations
An Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib (PON) Phase 2 PACE Trial (NCT01207440) in Patients (pts) with Ph+ Leukemia (Abstract #7550, Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant)2
Re-MIND Study: A Propensity Score-Based 1:1 Matched Comparison of Tafasitamab + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) (Abstract #8020, Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia)3
Safety and Efficacy of Pemigatinib Plus Pembrolizumab Combination Therapy in Patients (pts) with Advanced Malignancies: Results from FIGHT-101, an Open-Label Phase 1/2 study (Abstract #3606, Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology)
Capmatinib in Patients with METex14 -Mutated or High-Level MET -Amplified Advanced Non-Small-Cell Lung Cancer (NSCLC): Results from Cohort 6 of the Phase 2 GEOMETRY mono-1 study (Abstract #9520, Session: Lung Cancer—Non-Small Cell Metastatic)1
Pan-Cancer Analysis of FGFR1-3 Genomic Alterations to Reveal a Complex Molecular Landscape (Abstract #3620, Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology)
EHA Abstracts
Oral abstract presentations and e-posters accepted for presentation at EHA will be available on the on-demand Virtual Congress platform beginning Friday, June 12, 2020, at 8:30 AM CEST.
Oral Presentations
Addition of Parsaclisib, a PI3Kδ inhibitor, in Patients with Suboptimal Response to Ruxolitinib (Rux): A Phase 2 Study in Patients (Pts) with Myelofibrosis (MF) (Abstract #S216, Session: Novel Therapies and Pitfalls in MPN)
Ruxolitinib Versus Best Available Therapy in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: Overall Response Rate by Baseline Characteristics in the Randomized Phase 3 REACH2 Trial (Abstract #S255, Session: Stem Cell Transplantation – Clinical: Graft-Versus-Host Disease)1
GRAVITAS-301: A Randomized, Double-Blind Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids for Initial Treatment of Patients with Acute Graft-Versus-Host Disease (Abstract #S256, Session: Stem Cell Transplantation – Clinical: Graft-Versus-Host Disease)
Interim Analysis from the OPTIC Trial, a Dose-Ranging Study of 3 Starting Doses of Ponatinib (Abstract #S172, Session: Chronic Myeloid Leukemia (CML) Clinical)2
Re-MIND Study: Comparison of Tafasitamab + Lenalidomide (L-Mind) vs Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Abstract #S238, Aggressive Lymphomas: Observational Studies)3
E-Poster Presentations
Real-World Survival in Elderly Patients with Myelofibrosis in the United States: Ruxolitinib Exposed vs Unexposed (Abstract #EP1124, Session: Myeloproliferative Neoplasms – Clinical)
Real-World Survival in Elderly Patients with Myelofibrosis in the United States: Pre- vs Post-Ruxolitinib Approval (Abstract # EP1120, Session: Myeloproliferative Neoplasms – Clinical)
Machine-Learning to Predict Hydroxyurea (HU) Failure and Incidence of Thromboembolic Events (TEs) with HU vs Ruxolitinib Switch Therapy in Polycythemia Vera Patients (Abstract #EP1117, Session: Myeloproliferative Neoplasms – Clinical)1
Patient-Reported Physical, Emotional and Economic Impact of Myeloproliferative Neoplasms in an Expansion of the MPN Landmark Survey (Abstract #EP1112, Session: Myeloproliferative Neoplasms – Clinical)1
Ruxolitinib in PV Patients Resistant and/or Intolerant to Hydroxyurea: Interim Analysis of a European Multi-Centric Observational Study (Abstract #EP1115, Session: Myeloproliferative Neoplasms – Clinical)1
Treatment and Disease Management Practices in Patients with MPNs in 6 Countries: An Expansion of the MPN Landmark Survey (Abstract #EP1123, Session: Myeloproliferative Neoplasms – Clinical)1
Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Phase 2 PACE Trial of Ponatinib in Philadelphia Chromosome Positive (Ph+) Leukemia (Abstract #EP759, Session: Chronic Myeloid Leukemia (CML) Clinical)2
The Real–Life Study Evaluating the Efficacy and Safety of Ponatinib “Topase” Reveals Induction of Deep Molecular Responses in a Cohort of 75 TKI-Resistant or Intolerant patients with CML (Abstract #EP765, Session: Chronic Myeloid Leukemia (CML) Clinical)
Combination of Tafasitamab (MOR208) and Lenalidomide Enhances Tumor Cell Death of B-cell Lymphoma in Vitro (Abstract #EP1343, Session: Lymphoma Biology & Translational Research)3
Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (Mor208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Abstract #EP1201, Session: Aggressive Non-Hodgkin Lymphoma - Clinical)3
Expression of CD19 Antigen on Chronic Lymphocytic Leukemia Cells After Tafasitamab (Anti-CD19) Treatment: Phase I Trial Data (Abstract #EP671, Chronic Lymphocytic Leukemia and Related Disorders - Biology & Translational Research)3
For full session details and data presentation listings, please see the ASCO20 (https://meetinglibrary.asco.org ) and EHA25 (https://learningcenter.ehaweb.org/eha ) online programs.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com
and follow @Incyte
.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s or partner company’s ongoing clinical development pipeline, and whether or when any development compounds will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, its presentation plans for the upcoming ASCO and EHA meetings and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the Company’s dependence on its relationships with its collaboration partners; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ended March 31, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.
1 Novartis-sponsored; 2 Takeda-sponsored; 3 MorphoSys-sponsored
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005695/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Codethink Achieves Positive Functional Safety Assessment to IEC 61508 and ISO 26262 Standards for the Eclipse Trustable Software Framework30.10.2025 10:04:00 CET | Press release
Codethink announced that it has successfully achieved a positive and complete Functional Safety Assessment for the Eclipse Trustable Software Framework (TSF). Performed by exida, a globally recognised authority in functional safety, the assessment was conducted in accordance with IEC 61508 requirements, with domain experts ensuring full alignment and compatibility with ISO 26262, the automotive industry’s functional safety standard. The evaluation represents a major milestone in Codethink’s mission to transform how the world engineers, verifies, and trusts software. According to the assessment, “considering the process objectives of both IEC 61508 and ISO 26262, the specification of Trustable [Trustable Software Framework] and the reference implementation that maps Trustable tenets and assertions to the objectives in IEC 61508, it is determined that Trustable sets out an approach to software development which meets and in many cases exceeds the rigor and expectations established for so
GHK Capital-Backed Horizon Group Welcomes Kasper Diaz Sommer as Senior Vice President of Global Cruise Logistics30.10.2025 10:00:00 CET | Press release
Horizon Group, along with its subsidiaries Swift Marine and Delver Agents, proudly announces the appointment of Kasper Diaz Sommer as Senior Vice President (SVP) of Global Cruise Logistics, effective November 3, 2025. Based in Denmark, Kasper will lead the group’s global Cruise Logistics strategy, driving growth across Europe, Asia, and the Americas and strengthening Horizon’s role as the trusted logistics partner to the world’s leading marine and cruise operators. With over two decades of international leadership experience in freight forwarding, logistics, and maritime supply chains, Kasper is known for his hands-on leadership, customer-first mindset, and proven success in building high-performing global teams. “Kasper’s leadership will accelerate our strategy to deliver seamless, end-to-end logistics solutions for the world’s marine and cruise operators,” said Jeff McCorstin, CEO of Horizon. “His industry insight, strategic mindset, and passion for innovation align perfectly with ou
Ares Management to Acquire BlueCove30.10.2025 09:18:00 CET | Press release
Integrated Business to Form Newly Created Ares Systematic Credit Strategy Ares Management Corporation (NYSE: ARES) (“Ares”) announced today that one of its affiliates has entered into a definitive agreement to acquire the entire outstanding share capital of BlueCove Limited (“BlueCove”), a London-based systematic fixed income manager. Financial terms were not disclosed. The transaction is expected to close in the first quarter of 2026, subject to customary closing conditions, including regulatory approvals. Founded in 2018 by Alex Khein and Hugh Willis – who have respectively served as CEO and Executive Chairman – BlueCove has grown to become a leader in systematic credit investing. The firm is comprised of a highly experienced, long-tenured team of fixed income investment, engineering, and business infrastructure professionals specializing in systematic portfolio management. Through its proprietary technology and varied product offering, BlueCove invests in high-yield, corporate inves
Bybit Expands Partnership with Thredd to Globally Scale Multi-Currency Crypto-Linked Debit Cards30.10.2025 09:00:00 CET | Press release
Thredd, the leading next-generation global payments processor, today announced an expanded partnership with Bybit, the world’s second-largest cryptocurrency exchange by trading volume. The collaboration supports regional rollout of the Bybit Card—Bybit’s flagship multi-currency, crypto-linked payment card, bridging the gap between digital assets and everyday payments across key global markets. Thredd’s processing platform is built to scale and navigate regulatory requirements across regions. With a single connection, Bybit can configure market-specific programs that meet local compliance needs while retaining centralized visibility. This flexibility has enabled Bybit to rapidly expand across multiple markets with more on the horizon. Over 2 million users worldwide trust the Bybit Card for what matters most: competitive cardholder rewards, true global access, and effortless crypto-to-fiat convenience. Bybit leverages Thredd’s infrastructure to issue both virtual and physical Visa and Ma
Manhattan Associates Announces Appointment of Greg Betz As Chief Operating Officer30.10.2025 09:00:00 CET | Press release
Manhattan Associates Inc. (NASDAQ: MANH) today announced the appointment of Greg Betz to the position of Chief Operating Officer. A seasoned executive, Betz brings broad experience leading complex, international organisations. Most recently, Greg led Microsoft FastTrack, an organisation of more than 1,000 engineers in 35 countries that deliver cloud conversions to Microsoft's largest cloud customers. “Greg is an accomplished executive with a proven track record of delivering operational excellence to transform businesses and drive growth,” said Eric Clark, president and CEO of Manhattan Associates. “His appointment is yet another proof point of our commitment to expanding the depth and experience of our team to drive faster cloud adoption, and I am confident that his forward-thinking, result-oriented approach will play a pivotal role in our next phase of rapid growth.” In his new position, Greg will play a key role in helping scale the operational frameworks around conversions and rene
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom